Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Naperiglipron (LY3549492) in Healthy Subjects
NCT04758234Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of naperiglipron in type 2 diabetes mellitus (T2DM) and obesity, sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) at Day 76. Started Feb 2021; status: completed.
02
Drugs
naperiglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT04758234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04758234.